China Feihe Limited CFEIY

Company Overview

China Feihe Limited (OTC: CFEIY; HKEX: 6186) is a China-based dairy and nutrition company primarily focused on the production and sale of infant formula products. The company operates within the broader dairy, pediatric nutrition, and health food industries, with its core revenue driven by premium infant milk formula marketed under the Feihe brand portfolio. Its products are targeted mainly at families with newborns and young children in China, where the company has established a strong presence in the premium and ultra-premium infant nutrition market. In addition to infant formula, the company also produces adult milk powder, nutritional supplements, and related dairy products.

The company traces its origins to 1962 as a state-owned dairy operation in Heilongjiang Province and later transitioned into a privately controlled enterprise under founder Leng Youbin. Over time, China Feihe evolved from a regional dairy producer into one of China’s largest domestic infant formula companies, benefiting from rising consumer preference for locally produced premium nutrition products following industry-wide food safety concerns involving foreign and domestic competitors. The company’s vertically integrated supply chain, including dairy farming, raw milk sourcing, production, and distribution, is considered a significant competitive advantage in China’s infant nutrition sector.

Business Operations

China Feihe organizes its operations primarily around its Infant Formula Products business, which represents the vast majority of company revenue, alongside smaller contributions from Other Dairy Products and nutritional offerings. The company manufactures and distributes infant formula across multiple premium price tiers, including flagship brands such as Xingfeifan, Zhenzhi, and Super Feifan. Revenue is generated mainly through domestic retail channels, e-commerce platforms, maternal and child specialty stores, and direct distribution networks throughout China.

The company maintains a vertically integrated operating structure that includes dairy farming, raw milk procurement, research and development, manufacturing, logistics, and sales operations. Its production facilities are concentrated primarily in Heilongjiang Province and other regions within China. China Feihe has also invested in overseas milk sourcing and production capabilities, including operations in Canada through Canada Royal Milk ULC, which supports international raw material access and production diversification. The company collaborates with research institutions and pediatric nutrition experts to strengthen product development and scientific research capabilities.

Strategic Position & Investments

China Feihe’s strategic direction centers on premiumization, scientific research, product innovation, and expansion into broader child and family nutrition categories. The company has invested heavily in pediatric nutrition research, maternal health products, and advanced dairy processing technologies in an effort to strengthen brand differentiation in China’s competitive infant formula market. Management has consistently emphasized long-term investments in research and development, supply chain control, and consumer trust as key growth priorities.

The company has also pursued investments aimed at enhancing production security and international sourcing capabilities. Notable investments include the development of overseas dairy infrastructure through Canada Royal Milk ULC and continued expansion of domestic production facilities. In recent years, China Feihe has increased focus on functional nutrition products, children’s health products, and emerging nutritional science segments associated with early childhood development. The company has also participated in partnerships with universities and research institutions focused on maternal and infant health sciences.

Geographic Footprint

China Feihe’s primary market is Mainland China, where the company derives the overwhelming majority of its revenue and maintains extensive nationwide distribution coverage. Its headquarters are located in Beijing, while major production and dairy farming operations are concentrated in Heilongjiang Province, an important dairy-producing region in northeastern China. The company distributes products across urban and lower-tier city markets through retail chains, specialty mother-and-baby stores, supermarkets, and online commerce platforms.

Internationally, China Feihe maintains a more limited but strategically important operational footprint. The company has invested in dairy-related assets in Canada, particularly through its Canadian production and milk sourcing operations, to strengthen supply chain resilience and product quality assurance. Although its commercial exposure outside China remains relatively modest compared with domestic operations, the company’s international investments support its broader positioning as a premium infant nutrition provider with global sourcing capabilities.

Leadership & Governance

China Feihe was led and significantly shaped by founder Leng Youbin, who has been closely associated with the company’s long-term development strategy and emphasis on product safety, supply chain integration, and domestic brand leadership. The company’s governance structure reflects a combination of founder leadership and professional management oversight typical of large publicly listed consumer companies in China. Strategic priorities communicated by leadership have consistently focused on scientific innovation, premium brand positioning, and long-term consumer trust.

Key executives and leadership figures include:

• Leng Youbin – Chairman and Chief Executive Officer
• Liu Hua – Vice President
• Cai Fangliang – Chief Financial Officer
• Qi Ning – Vice President
• Zhu Deli – Vice President

The company is publicly listed on the Hong Kong Stock Exchange and operates under governance and disclosure standards applicable to listed issuers, including reporting through annual reports and other regulatory filings. Public disclosures indicate that management continues to prioritize research-driven growth, operational integration, and expansion within China’s premium infant nutrition market.